< >

HyperAcute Immunotherapy

NewLink Genetics has multiple HyperAcute immunotherapies currently under development in a variety of tumors

Phase 3 Trial in Pancreatic Cancer

Now enrolling patients with borderline resectable or locally advanced unresectable pancreatic cancer

Phase 2b/3 Trial in Lung Cancer

Now enrolling patients with progressive or relapsed non-small cell lung cancer (NSCLC)

Investor Relations

Keep up with the latest news and presentations
NewLink Genetics Corporation, Through Its Wholly Owned Subsidiary, BioProtection Systems Corporation, Secures a Letter Contract From the Defense Threat Reduction Agency for Testing and Evaluation of Ebola Virus Vaccine
August 05, 2014

NewLink Genetics Corporation Reports Second Quarter 2014 Financial Results
August 05, 2014

ANNOUNCEMENTS